Tech Digest

Regeneration of Pancreas Is Big News for Diabetics and Biotech Investors

Stay Up to Date!

Simply enter your email below and click SIGN UP!

112 Years Old ... Still The Life of the Party - Find out more here

February 27, 2017

Dear Reader,

A paper published in the journal Cell has taken the scientific world by storm. Its premise is so transformational, it’s being discussed by nutritional biologists, biogerontologists, and stem cell scientists. Investors and life extension advocates also have good reason to take note.

The title is, “Fasting-Mimicking Diet Promotes Ngn3-Driven β-Cell Regeneration to Reverse Diabetes.” In plain English, it means that a specific, temporary low-calorie diet activates pre-natal gene codes to grow beta or β-cells.

If the authors are correct, this could have a profound impact on your health, life span, and bank account.

America's Divided on President Trump's Handling of the Economy - Meet both sides at the 2017 Strategic Investment Conference - Register Now

The benefits of the fasting-mimicking diet

Diabetics know all too well that beta cells don’t regenerate once they’ve died. Once the genetic code that built your pancreas shuts down, the only way to replace beta cells is a costly surgical transplantation.

At least, that’s what we thought until now. This paper indicates that genetic “developmental” codes active in the womb can be reactivated. The implications of this are staggering.

I’ve written a great deal about the fasting-mimicking diet (FMD). It was developed by the director of the USC Longevity Institute Valter Longo, PhD. Longo created a short regimen of relatively severe calorie restriction after studying many forms of fasting and calorie restriction.

In animal trials, FMD has been shown to significantly reduce disease rates, including cancer. It has also been shown to increase health spans. Human trials would be long and costly, but the same improvements in biomarkers can be seen across species.

Our ancestors routinely experienced cycles of famine and feast. Research shows that FMD seems to activate ancient genetic adaptations to these cycles.

The benefits of FMD extend beyond weight loss. FMD triggers prolonged improvements in health. This includes improved blood pressure and glucose levels.

FMD also improves bone density while selectively removing belly or interstitial fat. And it does this without muscle loss. This is pretty much a miracle especially for older people who strength train for health reasons.

For clear legal reasons, Longo is saying “Do not try this at home,” (though my nutritional biologist wife and I do). But you might want to check out L-Nutra’s prepackaged FMD foods. Longo chairs the L-Nutra board and donates his profits to further research.

Here’s how FMD works

Though FMD’s ability to improve health is remarkable, I think the real news is how it does it. The paper states, “In human type 1 diabetes pancreatic islets, fasting conditions reduce PKA and mTOR activity and induce Sox2 and Ngn3 expression and insulin production.” This is exciting news.

What happens in mice? The summary states that it is “Ngn3-driven generation of insulin-producing β cells, resembling that observed during pancreatic development.” In other words, mice utilize developmental genetic programs to grow the β cells that store and control insulin. It appears this happens in humans too.

The paper suggests that “lineage reprogramming” occurs. That means that cells’ genetic profiles are changing to become other types of cells. In this case, they are becoming functional β cells.

This is great news for diabetics, but it’s important for other reasons as well. The bigger news is that we may turn on pre-natal developmental genetic programs to heal hearts, brains, kidneys, eyes, joints, and more.

Might there be a drug or drugs that could induce this sort of genetic reprogramming of adult cells? In fact, we believe there are. The study speculates that “the effect of the FMD on pancreatic regeneration in type-1 diabetics could be mimicked or enhanced by pharmacological inhibition of the (mTOR and PKA) pathways.

One drug Longo used for that purpose is rapamycin. I discussed this drug last week in an article about Mount Tam Biotechnologies. Once again, the entire Longo paper on regeneration of the pancreas via FMD is available online here.

Another approach to reactivating these embryonic gene programs is being developed by Michael West, PhD, co-CEO of BioTime (*see disclosure below). His explanation of Induced Tissue Regeneration is available online.

Together, these are pieces of a scientific breakthrough that will, I’m convinced, profoundly change everything we think we know about medicine, health, and the human life span.

(*Disclosure: The editors or principals of Mauldin Economics have a position in this security. They have no plans to sell their position at this time. There is an ethics policy in place that specifies subscribers must receive advance notice should the editors or principals intend to sell.)

Sincerely,
Patrick Cox
Patrick Cox
Editor, Transformational Technology Alert

Mauldin Economics

 

Stay in the Loop on Life-Extending Research
with Patrick Cox's Tech Digest

Tech Digest


Your privacy is very important to us. Please review our Privacy Policy.

Tags:

« Back to Articles

112 Years Old ... Still The Life of the Party - Find out more here

Discuss This

0 comments

We welcome your comments. Please comply with our Community Rules.

Comments

patrick.bria@tuckerbria.com

Feb. 28, 3:41 p.m.

Patrick, what do you know about Orgenesis and their stem-cell work?

Thanks for MNTM and BTX.  I have them on my radar.

Pat Bria


Use of this content, the Mauldin Economics website, and related sites and applications is provided under the Mauldin Economics Terms & Conditions of Use.

Unauthorized Disclosure Prohibited

The information provided in this publication is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Mauldin Economics reserves all rights to the content of this publication and related materials. Forwarding, copying, disseminating, or distributing this report in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.
Participation in such activity is grounds for immediate termination of all subscriptions of registered subscribers deemed to be involved at Mauldin Economics’ sole discretion, may violate the copyright laws of the United States, and may subject the violator to legal prosecution. Mauldin Economics reserves the right to monitor the use of this publication without disclosure by any electronic means it deems necessary and may change those means without notice at any time. If you have received this publication and are not the intended subscriber, please contact service@mauldineconomics.com.

Disclaimers

The Mauldin Economics website, Yield Shark, Thoughts from the Frontline, Patrick Cox’s Tech Digest, Outside the Box, Over My Shoulder, World Money Analyst, Street Freak, Just One Trade, Transformational Technology Alert, Rational Bear, The 10th Man, Connecting the Dots, This Week in Geopolitics, Stray Reflections, and Conversations are published by Mauldin Economics, LLC. Information contained in such publications is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained in such publications is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed in such publications are those of the publisher and are subject to change without notice. The information in such publications may become outdated and there is no obligation to update any such information. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments.
John Mauldin, Mauldin Economics, LLC and other entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications or web site. Corporate policies are in effect that attempt to avoid potential conflicts of interest and resolve conflicts of interest that do arise in a timely fashion.
Mauldin Economics, LLC reserves the right to cancel any subscription at any time, and if it does so it will promptly refund to the subscriber the amount of the subscription payment previously received relating to the remaining subscription period. Cancellation of a subscription may result from any unauthorized use or reproduction or rebroadcast of any Mauldin Economics publication or website, any infringement or misappropriation of Mauldin Economics, LLC’s proprietary rights, or any other reason determined in the sole discretion of Mauldin Economics, LLC.

Affiliate Notice

Mauldin Economics has affiliate agreements in place that may include fee sharing. If you have a website or newsletter and would like to be considered for inclusion in the Mauldin Economics affiliate program, please go to http://affiliates.pubrm.net/signup/me. Likewise, from time to time Mauldin Economics may engage in affiliate programs offered by other companies, though corporate policy firmly dictates that such agreements will have no influence on any product or service recommendations, nor alter the pricing that would otherwise be available in absence of such an agreement. As always, it is important that you do your own due diligence before transacting any business with any firm, for any product or service.

© Copyright 2017 Mauldin Economics